Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease

Blood Platelet Disorders Clinical Trial

Official title:

An Exploratory Phase II Dose Escalation Study of Eltrombopag in MYH9 Related Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01133860
• Other study ID #: Eltrombopag-MYH9-2008
• Status: Completed
• Phase: Phase 2
• First received: May 28, 2010
• Last updated: July 22, 2011
• Start date: January 2009
• Est. completion date: June 2010

Study information

• Verified date: July 2010
• Source: IRCCS Policlinico S. Matteo
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The term MYH9-related disease (MYH9RD) includes four genetic disorders: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome. All these disorders derive from mutation of a unique gene, named MYH9, and they have been recognized as different clinical presentations of a single illness that was named MYH9RD. All patients affected by MYH9RD present since birth with thrombocytopenia, which can result in a variable degree of bleeding diathesis; some of them subsequently develop additional clinical manifestations, such as renal damage, sensorineural hearing loss, and/or presenile cataracts. Eltrombopag is an oral thrombopoietin receptor agonist that stimulates proliferation and differentiation of megakaryocytes, the bone marrow cells that produce blood platelets. This drug is effective in increasing platelet count in healthy volunteers, as well as in patients affected by some acquired thrombocytopenias, such as idiopathic thrombocytopenic purpura and HCV related thrombocytopenia. The purpose of this study is to determine if eltrombopag, administered orally at the dose of 50 or 75 mg/daily for up to 6 weeks, is effective in increasing platelet count of patients affected by MYH9RD. Further aims of this study are to test if eltrombopag is effective in reducing bleeding tendency of MYH9RD patients; to evaluate safety and tolerability of eltrombopag in patients with MYH9RD; to evaluate in vitro function of platelets produced during therapy in patients responding to this drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: June 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Age 16 years or more

• Confirmed diagnosis of MYH9-related disease

• Average platelet count for the previous year less than 50x10e9/L

• Written informed consent

Exclusion Criteria:

• Diseases known to involve the risk of thromboembolic events (e.g. atrial fibrillation)

• History of thrombosis within 1 year

• Use of drugs that affect platelet function (including but not limited to, aspirin, clopidogrel or NSAIDS) or anti-coagulants

• Females who are pregnant or nursing (a negative pregnancy test in required before enrollment of fertile women)

• Formal refusal of any recommendation of a safe contraception

• Alcohol or drug addiction

• Altered renal function as defined by creatinine of 20 mg/L or more

• Any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioral problems. HCV positivity and liver diseases will not be considered an exclusion criterion since a phase II study showed that eltrombopag was effective and safe in this patient population.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Blood Platelet Disorders
• Thrombocytopenia

Intervention

Drug:
• eltrombopag
Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.

Locations

Country	Name	City	State
Italy	Azienda Ospedaliero-Universitaria di Padova, Unità di Medicina Generale e Patologia Speciale	Padova
Italy	Fondazione IRCCS Policlinico San Matteo, Unità di Medicina III	Pavia
Italy	Policlinico Monteluce, Sezione di Medicina Interna e Cardiovascolare	Perugia

Sponsors (6)

Lead Sponsor	Collaborator
IRCCS Policlinico S. Matteo	Azienda Ospedaliera di Padova, Azienda Ospedaliera di Perugia, Fondazione Telethon, GlaxoSmithKline, University of Pavia

Country where clinical trial is conducted

Italy, 

References & Publications (5)

Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007 Nov 29;357(22):2237-47. — View Citation

McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH; TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36. — View Citation

Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, Ghiggeri GM, Ravazzolo R, Savino M, Del Vecchio M, d'Apolito M, Iolascon A, Zelante LL, Savoia A, Balduini CL, Noris P, Magrini U, Belletti S, Heath KE, Babcock M, Glucksman MJ, Aliprandis E, Bizzaro N, Desnick RJ, Martignetti JA. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet. 2000 Sep;26(1):103-5. — View Citation

Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, Nigro A, Noris P, Gangarossa S, Rocca B, Gresele P, Bizzaro N, Malatesta P, Koivisto PA, Longo I, Musso R, Pecoraro C, Iolascon A, Magrini U, Rodriguez Soriano J, Renieri A, Ghiggeri GM, Ravazzolo R, Balduini CL, Savoia A. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore). 2003 May;82(3):203-15. — View Citation

Seri M, Savino M, Bordo D, Cusano R, Rocca B, Meloni I, Di Bari F, Koivisto PA, Bolognesi M, Ghiggeri GM, Landolfi R, Balduini CL, Zelante L, Ravazzolo R, Renieri A, Savoia A. Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet. 2002 Feb;110(2):182-6. Epub 2001 Dec 14. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response to Drug Based on Platelet Count at the End of Therapy	The primary endpoints were the achievement of a platelet count over 100 x10e9/L or at least 3 times the baseline value (major response), or at least twice the baseline value but less than major response (minor response). The overall response to therapy is reported. Platelet count was measured at the end of therapy (21 or 42 days, see study design) by phase-contrast microscopy.	21 days and/or 42 days of therapy, 15 and 30 days after the end of therapy	No
Secondary	Bleeding Tendency Assessed by WHO Bleeding Score	The percentage of patients with bleeding diathesis (grade 1, i.e. cutaneous bleeding, or grade 2, i.e. mild blood loss, according to WHO bleeding score) was calculated at baseline and at the end of therapy. The results are expressed as the mean change in the percentage of patients with bleeding diathesis (95%CI).	21 days and/or 42 days of therapy, 15 and 30 days after the end of therapy	No
Secondary	All Types of Adverse Events	All type of adverse events were registered.Results indicate the number of participants who experience a side effect of the drug.	21 days and/or 42 days of therapy, 15 and 30 days after the end of therapy	Yes
Secondary	in Vitro Function of Platelets Produced During Therapy in Responding Patients	in vitro platelet function will be assessed in patients achieving a platelet count of 100 x10e9/L or more at the end of the therapy	21 days or 42 days of therapy	No